Premature ovarian failure after childhood cancer and risk of metabolic syndrome: a cross-sectional analysis.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
21 May 2021
Historique:
received: 04 11 2020
accepted: 29 04 2021
pubmed: 30 4 2021
medline: 1 6 2021
entrez: 29 4 2021
Statut: epublish

Résumé

Female childhood cancer survivors (CCS) are at risk of several late effects, such as metabolic syndrome (MetS) and premature ovarian insufficiency (POI). The objective is to study if POI is associated with risk of MetS and increased cardiovascular risk in CSS. A cross-sectional study with a median time since the cancer diagnosis of 25 (12-41) years. Patients and controls were recruited from the South Medical Region of Sweden. The study included 167 female CCS, median age 34 (19-57) years, diagnosed with childhood cancer at median age 8.4 (0.1-17.9) years together with 164 controls, matched for age, sex, ethnicity, residence, and smoking habits. All subjects were examined with fasting glucose, insulin, HbA1c, and lipid profile. Fat mass was calculated with dual-energy X-ray absorptiometry (DXA), and questionnaires for medication were obtained. Detailed information of cancer treatment was available. POI was present in 13% (22/167) among CCS (hypothalamic/pituitary cause excluded) and in none among controls. MetS was present in 14% (24/167) among all CCS (P = 0.001), in 23% (5/22) of those with POI (P < 0.001), compared with 4% (6/164) among controls. OR for MetS in all CCS compared with controls was 4.4 (95% CI: 1.8, 11.1) (P = 0.002) and among CCS with POI the OR was 7.7 (CI: 2.1, 28.1) (P = 0.002). The prevalence of MetS was higher in females treated for childhood cancer compared with controls, and the presence of POI significantly increased the risk of developing MetS.

Identifiants

pubmed: 33914702
doi: 10.1530/EJE-20-1275
pii: EJE-20-1275
doi:
pii:

Substances chimiques

Antineoplastic Agents 0
Antineoplastic Agents, Alkylating 0
Blood Glucose 0
Cholesterol, HDL 0
Cholesterol, LDL 0
Glycated Hemoglobin A 0
Insulin 0
Triglycerides 0
hemoglobin A1c protein, human 0
Anti-Mullerian Hormone 80497-65-0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-75

Auteurs

Axel Netterlid (A)

Department of Pediatrics, Helsingborg Hospital, Lund University, Helsingborg, Sweden.

Helena Mörse (H)

Department of Pediatrics, Pediatric Oncology and Hematology, Skåne University Hospital, Lund University, Lund, Sweden.

Aleksander Giwercman (A)

Department of Reproductive Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.

Emir Henic (E)

Department of Reproductive Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.

Kristina E Åkesson (KE)

Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden.

Eva-Marie Erfurth (EM)

Department of Endocrinology, Pediatric Endocrinology, Skåne University Hospital, Lund University, Lund, Sweden.

Maria Elfving (M)

Department of Pediatrics, Pediatric Endocrinology, Skåne University Hospital, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH